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ABSTRACT 
 
Background 
A growing concern about possible age-related inequities in health care access has emerged in the 
increasing debate on the challenges of population ageing and health in sub-Saharan Africa. Older 
persons may experience systematic exclusion from health services.  Viewed as one of the poorest, 
most marginalized groups in SSA societies, older people are deemed to lack access to even basic, 
adequate health care.  There is an assumption, furthermore, that older persons have less access to 
required health services than do younger age-groups.  This suggests an element of age-related 
inequity.  One possible indicator of age-related inequity may be found through measuring the relative 
availability of essential medicines for chronic non-communicable diseases (NCD), relative to the 
availability of medicines for communicable diseases (CD). 
 
Aim and objectives 
The aim of the study was to compare the availability of essential medicines for NCD and CD in 
Kenya, as an indicator of age-related inequities in access to health care in Kenya. 
 
The three study objectives were as follows, in public and mission facilities in Kenya: 
1. To assess the availability of medicines for the following CD: diarrhoea, HIV, malaria, 
pneumonia and other infections 
2. To assess the availability of medicines for the following NCD common in older populations: 
arthritis, diabetes, glaucoma, gout, heart disease, hypertension and Parkinson’s disease 
3. To compare the availability of medicines for CD and NCD and draw conclusions on possible 
age-related inequities in access. 
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Study design 
Using an adapted version of the HAI / WHO methodology, a cross sectional descriptive survey of 
medicines availability was conducted. HAI and WHO collaboratively developed a standardized and 
validated methodology for comprehensively measuring medicines availability, as well as prices, 
affordability and price components.  The survey manual, launched in 2003 and revised in 2008, is 
available to the public. The methodology involves collecting data on the availability and price of 
medicines found in a sample of health facilities across sectors of interest within national health 
systems.  If the specific medicine, dose and form being surveyed is available on the day of the 
survey, then the medicine is documented as being available. 
 
Methods 
Random sampling was carried out in six of Kenya’s eight provinces, targetting ten facilities per 
province.  Data on availability of the targeted medicines was collected by trained data collectors on 
pilot-tested data collection forms adapted from the standardized WHO / HAI methodology.  The list 
of medicines included sixteen for communicable diseases to treat infections such as diarrhoea, HIV, 
malaria, and pneumonia and twelve medicines used to treat non-communicable diseases such as 
diabetes, arthritis, hypertension, gout, glaucoma, stroke and Parkinson’s disease.  Availability of 
medicines was noted by physical observation by a data collector, and calculated as the percentage of 
facilities where a medicine was found on the day of data collection.  The availability of brands and 
generics was not distinguished and were combined to establish availability of each medicine. Overall 
availability of all CD and NCD medicines was compared, and within each category between rural 
and urban areas and between mission and public facilities. 
 
The Ministry of Health was informed of the survey and provided the data collectors with an MOH 
endorsement letter.  The names of facilities participating in the study were recorded on the data 
collection forms, but not reported.  No data on individual patients was collected, and no patients were 
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interviewed for this survey.   
 
Data were entered into an Excel file and exported to and analyzed with SPSS. 
 
Results 
A total of 56 facilities were surveyed: 49 in the public sector and 7 in the mission sector, giving a 
facility response rate of 93%.  Thirty facilities were located in rural settings and 26 were in urban 
settings.   
 
More CD medicines were available than medicines for NCD.  Of a total of 896 individual 
observations of CD medicines, 632 (70.5%) were recorded as available on the day of visit, compared 
to 306 (45.5%) of 672 possible individual observations of NCD medicines. These differences were 
highly significant statistically (chi-square=98.8, p<0.001). Furthermore, comparison of availability 
between urban and rural areas showed statistically significant differences for NCD medicines (40.6% 
vs. 51.3%, p=0.007), but not CD medicines (72.5% vs. 68.3%, p=0.190). There were no significant 
differences in availability of medicines in mission compared to public facilities.  
 
Conclusions  
This study reveals the low relative availability of medicines for NCDs in Kenya’s public and mission 
sector.  Medicines for NCDs were less available in rural vs. urban facilities, but there was no rural 
vs. urban difference in medicines for CDs.  While more research should be carried out to understand 
the reasons behind these findings, immediate attention to the supply and financing of medicines for 
NCDs is urgently needed.  The relatively lower availability of medicines for NCDs than for CDs may 
be an indicator of age-related inequities in access to health care in Kenya and calls for more 
investigations on equity and access to health for older people in Kenya. 
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INTRODUCTION 
 
Inequities in access to health care in sub-Saharan Africa 
The World Health Organization (WHO) Constitution states "the enjoyment of the highest attainable 
standard of health is one of the fundamental rights of every human being" (WHO, 2008a).  The 
International Covenant on Economic, Social and Cultural Rights further defines “access to health 
care” as “the availability of specific services; the accessibility of services to the public; the 
acceptability of the services to different cultures, sexes, and age groups; and the quality of the 
services” (ICESCR, 2000).  The specifics of “accessibility of services to the public” are further 
developed through defining its four interrelated dimensions: non-discrimination, physical, economic 
and information accessibility (ICESCR, 2000). 
 
Research on inequity (which is defined as unnecessary, avoidable, unfair and unjust differences 
(Whitehead, 1992)) in access to health care in sub-Saharan Africa (SSA) has intensified in recent 
years, as part of a growing global concern with health as a human right, as well as the social 
determinants of health, the millennium development goals, and universal access to health care 
including medicines (Braveman and Gruskin, 2003;Whitehead, Dahlgren and Evans, 2001; WHO, 
2008a; World Bank, 2005).  The research has established that poor people have less access to health 
care – and experience health inequities – than more advantaged people.  Poor people have less access 
to immunizations, contraception, treatments at health facilities for paediatric diseases like pneumonia 
and diarrhea, and maternal health services including assisted deliveries (Mutangadura, Gauci,  
Armah, Woldemariam, Ayalew and Egu, undated; Wagstaff, 2002). 
 
The common focus of the equity debate in SSA has been on the inability of the poor to access 
required health care due to cost, distance to health facilities (geographical accessibility) and other 
capacity barriers such as health-seeking behaviour and health knowledge (McIntyre et al., 2006; 
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Onwujeke, 2005). 
 
Research on peoples’ access to health care to date have primarily examined access by socio-
economic status such as household indicators of income, expenditure levels or wealth indicators 
(material assets), and geographical location (rural vs. urban) (Chuma, Gilson and Molyneux, 2007).  
While the evidence on health inequity is established for poor vs. more advantaged people, very little 
attention has been given to the exploration and analysis of potential inequities in health care access 
within poor households and/or poor populations (Bakeera et al., 2009; Braveman and Gruskin, 
2003).  Targeted data analyses have been completed on access to health care for children (such as 
immunization rates and access to malaria treatment) (WHO, 2009) but indeed few other analyses on 
more specific access inequities have been done.  To understand if there are also inequities within 
poor populations, sub-categories of these populations would have to be examined in depth.   
 
Concerns on age-related inequities in access to health care 
The challenges of population ageing and health in SSA have led to a growing debate about possible 
age-related inequities in health care access (Aboderin, 2009; Aboderin and Ferreira, 2009).  The 
debate takes note of recent demographic projections of rapid growth in SSA’s older population — 
from 43 million today to 160 million by 2050 (a sharper rise than for any other world region) 
(UNPD, 2010) — and revolves around the risks and vulnerabilities of older people to poor health 
outcomes (Aboderin, 2011). 
 
A key concept in this debate is that older persons experience systematic exclusion from health 
services.  As one of the poorest, most marginalized groups in SSA societies, older people are deemed 
to lack access to even basic, adequate health care.  There is an assumption, furthermore, that older 
persons have less access to required health services than do younger people.  This implies a level of 
age-related inequity (Aboderin and Kizito, 2010). 
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Preliminary indications of such disparities come from a small number of small-scale qualitative 
investigations and secondary analyses of national household survey data sets (Aboderin, 2009; 
McIntyre, 2004; HAI Africa, 2008).  However, from these analyses, no absolute evidence of age-
related inequities in health care access exists thus far (Aboderin, 2011).  
 
Establishing concrete evidence for age-related disparities would require at least an examination of 
individual data on health service use (treatment-seeking behaviour, cost burdens, health knowledge) 
and receipt of care (disease prevention, diagnosis, treatment) among older persons compared to 
younger age-groups.  A further analysis could also be carried out within health systems of the 
relative availability of basic health services (primary care facilities, essential medicines, diagnostic 
tests) for old age-related conditions, relative to the provision of services for diseases of younger age-
groups (Aboderin and Kizito, 2010). 
 
Essential medicines 
The WHO concept of essential medicines was developed over thirty years ago (WHO, 2010).  
Essential medicines are defined as:  
“those which satisfy the priority health care needs of the population.  They are selected with 
due regard to public health relevance, evidence on efficacy and safety, and comparative cost-
effectiveness.  They are intended to be available within the context of functioning health 
systems at all times in adequate amounts, in the appropriate dosage forms, with assured 
quality and adequate information, and at a price the individual and the community can 
afford.” (WHO, 2010). 
 
Access to essential medicines is an integral part of the human right to health (ICESCR, 2000) and 
encompasses availability, affordability and appropriate use. As such, the availability of essential 
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medicines to populations is one way of evaluating inequity in access to health care. 
 
Older and younger populations require different ‘baskets’ of essential medicines to meet their 
priority health needs:  while essential medicines for older persons must include medicines for key 
chronic non-communicable diseases (NCD), those for younger age-groups do not. In SSA and 
globally, the leading causes of morbidity, disability and mortality in older populations are chronic 
NCD whose risk rises sharply with age: in particular hypertension, diabetes, stroke, glaucoma, heart 
disease, Parkinson’s disease, and musculo-skeletal conditions including arthritis.  In contrast, the 
disease burden of children and younger-age adults in SSA is dominated by communicable 
(infectious) diseases (CD) and non age-related NCD (such as asthma) (WHO, 2008b).  
 
Initial inspection of data from WHO / HAI national surveys on Medicine Prices, Availability, 
Affordability and Price Components in SSA (HAI / WHO, 2010), indeed suggests a relatively lower 
availability and affordability of chronic NCD essential medicines compared to those for CD.  Further 
indications to this end come from preliminary review on medicines policy in Kenya which reveal that 
few medicines for NCD are supplied to the lowest level (rural) health facilities (Kenya Medical 
Supplies Agency, 2008).  
 
Finally, the significant international focus on increasing access to medicines for HIV, tuberculosis, 
and malaria through a number of well-funded multilateral Global Health Initiatives may indicate a 
potentially discriminatory prioritization of these communicable diseases over chronic NCD. 
 
Kenyan elderly: demographics, health system access, health profile, access to medicines 
In 2005 the population of people aged 60 and older in Kenya was estimated to be 1.4 million 
(Aboderin and Gachuhi, 2007) and had increased to 1.9 million by 2009 (NCAPD, 2012).  This 
population is forecasted to grow rapidly to 8.02 million by 2050, representing 10% of the total 
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population (Aboderin and Gachuhi, 2007) and is expected to continue to increase both in absolute 
number and total population share (NCAPD, 2012).  Regardless of the significance of Kenya’s 
elderly people, both in terms of size and growth rate, there is little data on the health status of this 
population or their use of the health system.  Indeed, the most recent demographic and health survey 
was done in Kenya in 2008 with the aim of providing information to monitor and evaluate the 
population and health situations in the country (Kenya Bureau of Standards, 2008).  The target age 
groups, however, were 15 – 49 (women) and 15 – 54 (men); no older persons were interviewed.   
 
Some evidence on health-related issues for older people can be extracted from the 2005 Kenya 
Household Budget Survey (KIHBS, 2005) which revealed that many older people had chronic 
illnesses, with prevalence increasing proportionately across increasing age bands.  Conversely, 
however, older people under-utilized health services more commonly than younger people do, in 
both rural and urban setting (KIHBS, 2005).  This may be due to older peoples’ experiences 
surrounding access barriers (mainly financial) and exclusion from services (Aboderin, 2011), and 
their perceptions of the lack of quality in public health services (Aboderin and Kitzito, 2010). 
 
Kenya’s health system is guided by its Health Sector Strategic Plan, which is informed by various 
partnerships, policy documents and commitments, including the Health Policy, the new Vision 2030, 
Kenya’s 2010 constitution, and health resolutions and treaties agreed to at international level.  Five-
year strategic plans are developed to meet the overall goals and objectives of the health sector, and 
are implemented based on the Kenya Essential Package for Health (KEPH) approach.  The KEPH 
focuses on interventions towards the improvement of health at six levels, from the community up to 
national referral hospital level. 
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The public sector is the backbone of the health system, with significant partners in the private sector 
(including private-for-profit, non-governmental, and faith-based partners).  Indeed, public facilities 
remain the major provider of health services to Kenyans, accounting for 53% of health facilities 
(MOH, 2008) and 59% of all in-patient admissions (MOH, 2007).  Public facilities also account for 
57% of total outpatient visits, whereas private and faith-based health facilities account for 18% and 
6% respectively, including 15% of outpatient visits being direct to a retail pharmacy (MOH, 2008). 
 
Public, and some mission, sector health facilities are provided medicines through the government’s 
central medical and supply agency.  The agency carries out centralized bulk procurement of essential 
medicines with funds from the government and development partners.  Many medicines are provided 
free of charge or at subsidized prices, therefore offering the best affordability option for poor people 
(MOH, WHO, HAI Africa, 2010).  There are multiple, parallel medicines supply systems in Kenya, 
even within the public sector specifically.  Vertical programs which include targeted medicines 
supply exist for treatment programs such as HIV, tuberculosis and malaria however non-
communicable diseases do not receive a specific focus in either vertical programming or medicines 
supply.   
 
Insufficient funding for medicines and the resultant erratic and inadequate supplies to health facilities 
are ongoing challenges, and over half of all Kenyans have limited access to essential medicines 
(WHO / HAI, 2010).  Research on medicines for chronic diseases specifically has generally been 
limited to the financial impact of treatment and prevention as a public health approach, but little 
research has focussed on medicine-specific price and availability, or peoples’ ability to afford these 
medicines.  Costing surveys in Kenya have revealed that affordability of treatments for chronic 
conditions is often much less than for acute conditions (WHO / HAI, 2010).  These findings are 
relevant to the situation of access for older people, due to their requirements of essential medicines 
for common chronic conditions to meet their priority health needs. 
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These initial indications, with their related evidence gaps, underscore the importance and timeliness 
of an investigation of the relative availability and affordability of essential medicines for chronic 
NCD in Kenya as one indicator of potential inequities in health for older people. 
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LITERATURE REVIEW  
 
NCDs 
Studies on NCDs reveal their increasing burden on mortality and high rates for risk factors – 
compounded with an ageing population – such as smoking, physical inactivity, increased blood 
pressure, obesity, increased cholesterol and increased blood glucose.  Health systems for NCDs in 
developing countries generally do not effectively manage and deliver primary health care services 
related to the ageing population, or the prevention and management of NCDs (Kotwani, 2010).  
Therefore, significant numbers of people continue to be at risk for NCDs, or are undiagnosed and 
untreated for an already underlying NCD (WHO, 2011).  Once considered diseases of an affluent 
lifestyle, it is becoming clear that NCDs have also evolved into diseases of poverty, with the poor 
being at risk of experiencing NCDs’ various contributory factors, such as unhealthy diets and 
inactivity. NCDs currently account for two out of every three deaths globally (WHO, 2011).  Of the 
NCD-related deaths in 2005, half were over age 70 (WHO, 2005). 
 
People with NCDs can place major burdens on health systems and resources because they require 
long-term treatment.  In the literature on availability of medicines, NCDs specifically or diseases 
mostly experienced by older people (such as osteoarthritis, glaucoma, gout, heart disease and stroke) 
are not well-differentiated from other NCDs such as asthma, depression and epilepsy – all of which 
may manifest themselves as chronic diseases from childhood. 
 
Medicines availability 
Systematic, comparative research on the availability, cost and affordability (measured in terms of the 
daily wages of lowest–paid unskilled government workers) of essential medicines has been 
conducted across many African countries (Cameron et al. 2009; HAI Africa, 2008; HAI / WHO, 
2010).  These surveys have found generally low availability of essential medicines (29.4 – 54.4%) in 
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the public health sector and unaffordable treatments for both acute and chronic diseases (Cameron et 
al., 2009).  
 
While literature on medicines availability in developing countries is increasing (Balasubramaniam, 
1996; Cameron et al., 2009; Myhr, 2000; HAI Africa, 2008; WHO / HAI, 2010), there is currently 
limited data on the relative availability of NCD medicines and older peoples’ access to medicines 
experiences. 
 
The majority of data on medicines availability have resulted from WHO / HAI medicine pricing 
surveys.  In 2001, Resolution 54.11 was passed at the World Health Assembly which directed the 
Director-General to investigate systems for voluntary monitoring of medicines prices with “a view to 
improving equity in access to essential medicines in health systems…” (WHO, 2001).  WHO and 
HAI led the development of the methodology, and a manual was released in 2003 for testing and 
revision.  To date, more than 50 standardized medicine price and availability surveys have been 
carried out globally.  The findings have revealed various barriers to access to medicines, including 
low availability, significant mark-ups on medicines along the supply chain which negatively affect 
patient prices, and low affordability especially for the most poor. 
 
The WHO / HAI survey methodology is rigorous and facilitates valid analysis of availability and 
prices across and among facilities, sectors, and regions.  It involves formal data collection of a pre-
established list of essential medicines at facility level using a random sampling frame to identify a 
nationally-representative list of targeted facilities.  Survey areas are randomly selected from 
population-stratified “administrative areas” at a distance no father than one day’s travel from the 
capital city.  The major public sector health facilities in the selected areas are selected to “anchor” 
the selection of the other health facilities and medicines outlets. It is noted that a number of 
validation studies (in addition to nine pilot studies) were done during the original process of 
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methodology development. The most important validation study was done in Peru on the sampling 
frame where it was found that sampling more regions, and those in areas greater than one days car 
travel from the capital, and in each area from more outlets a greater distance from the main public 
hospital produced the same price results as using the standard sampling frame (Madden, Meza, 
Ewen, Laing, Stephens and Ross-Degnan, 2010).   
 
A range of secondary analyses have been carried out from WHO / HAI data, including those on taxes 
and tariffs on medicines, procurement prices relative to international reference prices, and 
availability and price of medicines for different geographical locations such as urban vs rural. 
 
Secondary analyses of WHO / HAI survey data has been also been done for various disease groups, 
including an international comparison of chronic disease medicines regarding price and availability 
(Gelders, Ewan, Noguchi, and Laing, 2006).  The analysis was done medicine by medicine and there 
was no comparison to medicines for acute diseases.  The findings included generally lower 
availability in the public sector as compared to the private sector; it is noted however that only a 
limited number of NCD medicines were surveyed.   
 
A limited study in six low- and middle-income countries looked at the availability of selected 
medicines for heart disease, diabetes, chronic respiratory disease, glaucoma and palliative care.  
Malawi was the only African country included in the study, and the findings there revealed a 5% 
median availability of the 32 essential medicines in the public sector (Mendis et al., 2007). 
 
A secondary analysis of availability and price surveys from 36 developing and middle-income 
countries (including eight from Africa) presented overall findings for a basket of 15 medicines and 
specific findings for four medicines (two for CD and two for NCD) (Cameron et al., 2009).  The use 
of the standardized WHO / HAI methodology across all surveys allowed for a valid secondary 
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analysis to be done.  For eight surveys from African countries, overall public sector availability of 
the 15 medicines was 29.4%.  The two medicines for CD (amoxicillin and ciprofloxacin) had 
availability of 81% and 50% respectively as compared to the two medicines for NCD (glibenclamide 
and salbutamol) with availabilities of 37% and 14%.  No comment was made on these differences; 
there was more focus on price and affordability of medicines for acute vs chronic diseases.  While a 
conclusion on age-related inequities cannot be made from comparing only four medicines, the 
dramatic difference in availability arguably gives an indication of the need for more study. 
 
Data from 50 WHO / HAI medicine price and availability surveys from low and middle-income 
countries was analyzed to compare the availability of cardiovascular medicines (van Mourik, 
Cameron, Ewen and Laing, 2010) and 30 essential medicines for acute and chronic diseases 
(Cameron, et al., 2011).  The findings included generally low availability of medicines for 
cardiovascular medicines, medicines for other chronic diseases, and medicines for acute diseases. 
Chronic disease medicines had the lowest availability: when the public sector data was analyzed, 
chronic disease medicines were 36% available (26% for cardiovascular disease medicines 
specifically) as compared to 53.5% availability of medicines for acute conditions. The least available 
chronic disease medicines were those used to manage asthma, epilepsy, depression and hypertension. 
The authors called for a greater response towards the ongoing epidemiological transition in 
developing countries, and called for more, current, and country specific monitoring of availability 
and price of medicines for chronic diseases.  The study did not specifically consider chronic 
medicines required by older people. 
 
The standardized WHO / HAI methodology measures both availability and price (WHO / HAI, 
2010).  In summary, there is enormous variability in both price and availability of medicines across 
regions, and within countries and health systems (Balasubramaniam, 1996; WHO / HAI, 2010).  
Prices are usually not rationalized with respect to international reference prices (Balasubramaniam, 
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1996) and impose unfair burdens on the most poor and vulnerable populations (HAI Africa, 2008).  
Indeed, prices in developing countries are often higher (even double) than those in the developed 
world such as Europe or North America (Myhr, 2000; WHO / HAI, 2010).  While prices are always 
lowest in the public sector, availability is also generally lowest in this sector (WHO / HAI, 2010).  
Unable to get the medicines they need at public health facilities, people are thus driven to purchase 
medicines that are more expensive at private or mission health services (WHO / HAI, 2010; HAI 
Africa, 2008) or, to go without medicines. 
 
Limitations 
For all these studies, the standardized WHO / HAI methodology and recommended sampling frames 
were used.  One of the methodological limitations is that availability is measured on the day of the 
survey and may not reflect availability over time; the findings reflect only an estimate of the 
situation.  Furthermore, an ideal availability / price monitoring model would involve collecting data 
from a large number of sites and outlets scattered around the country.  To make the monitoring 
feasible and cost-efficient however, the validated (see above) methodology uses smaller samples of 
geographic areas and price tracking sites. 
 
Finally, there are limitations of these surveys as an indicator of age-related inequities, including few 
medicines assessed, and which chronic diseases were chosen (such as asthma, epilepsy and 
depression, all of which may manifest in childhood and are not considered chronic diseases only of 
the elderly.) 
 
Equity issues are inherent in the findings of all the price and availability studies, as poor people are 
the most affected when experiencing low availability and high prices.  Age-related inequities, 
however, have not been considered in any of the price and availability surveys. 
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METHODOLOGY 
 
Study Aims and Objectives 
The aim of the study was to compare the availability of essential medicines for non-communicable 
diseases (NCD) and communicable diseases (CD) in Kenya, as an indicator of age-related inequities 
in access to health care in Kenya. 
 
The three study objectives were as follows: 
In public (and some mission) facilities in Kenya: 
1. To assess the availability of medicines for the following CD: diarrhoea, HIV, malaria, 
pneumonia and other infections 
2. To assess the availability of medicines for the following NCD common in older populations: 
arthritis, diabetes, glaucoma, gout, heart disease, hypertension and Parkinson’s disease 
3. To compare the availability of medicines for CD and NCD and draw conclusions on possible 
age-related inequities in access. 
 
Study Design 
Using an adapted version of the HAI / WHO methodology, a cross sectional descriptive survey of 
medicines availability was conducted.  Since little is known about possible age-related inequities in 
access to medicines, undertaking a descriptive study was a rational approach to first establishing the 
reality of the situation through observation, measurement and documentation (Beaglehole, Bonita 
and Kjellstrom, 1997). 
 
Definition of Terms 
Essential Medicines – as per WHO definition above 
Communicable Diseases (CDs) – treatable, infectious diseases 
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Non-communicable Diseases (NCDs) – chronic conditions, such as heart and lung disease, cancer, 
osteoarthritis, hypertension, diabetes, Parkinson’s disease 
Older / elderly – over the age of 60 years 
Urban – towns with more than 50 000 population 
Rural – towns at least 25km from the urban centre (for Nairobi, rural is defined as slum areas) 
 
Study Population  
The study population was all health facilities (public and mission) in Kenya.  
 
Sampling Procedure and Sample Size 
When using the WHO / HAI price and availability survey methodology, a sample size of thirty 
facilities per targeted health sector pillar (e.g. public, private, mission, etc.) has been shown with a 
validation study to adequately represent the availability and price situation in the country as a whole 
with minimum bias (Madden, Meza, Ewen, Laing, Stephens and Ross-Degnan, 2010). 
 
Multi-stage random sampling was done to select facilities to survey.  Six survey areas, representing 
six of the eight provinces were chosen as a representative sample for the country, which included the 
capital city province, and five more provinces selected using simple random sampling among all 
which are reachable within one day travel from the capital city.  In each province selected, the main 
public hospital was chosen to “anchor” the sample.  Lists were made of all public and mission health 
facilities within three hours’ travel from the six main hospitals, and ten facilities per survey area were 
randomly selected from the lists, again by drawing random numbers. 
 
The facilities in each sample were chosen from the spectrum of the public and mission sectors: from 
dispensaries, health centres, and sub-district / district hospitals (classified as “levels II, III and IV” in 
Kenya’s health system classification scheme for both the public and mission sectors) and were sub-
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categorized into rural and urban settings.  Urban was defined as towns with populations greater than 
50 000, while rural was defined as towns (with populations less than 50 000) at least 25km from the 
urban centre. 
 
The list of medicines sampled for the survey included sixteen medicines for the most common 
communicable diseases in Kenya, and twelve medicines for chronic non-communicable disease 
commonly diagnosed in older people such as cardiovascular diseases, stroke, hypertension, gout, 
glaucoma, arthritis, Parkinson’s disease and diabetes.  All medicines were referenced from the Kenya 
Essential Medicines List 2010 and are found in Annex 4.  They were selected for study by the author, 
based on the Kenya EML, relevant Standard Treatment Guidelines, and after discussions and 
consensus with the MOH Department of Pharmacy and the WHO National Medicines Advisor.  It is 
noted that medicines for tuberculosis were excluded from the list of most common communicable 
disease medicines, given that they are kept in separate, specialized clinics within health facilities and 
access to their availability and price data may often not be readily available. 
 
Data Collection 
Data on availability of the targeted medicines were collected over one week in April 2012 by twelve 
data collectors (working in pairs) on pilot tested data collection forms adapted from the standardized 
WHO / HAI methodology.  The data collectors selected included pharmaceutical technologists and 
non-technical people who had prior experience in health and medicines surveys.  They were 
collaboratively trained at central level by WHO and HAI Africa on the methodology, objectives of 
the project, and the data collection forms.  Availability of medicines was noted by physical 
observation by the data collector on the day of data collection.  A copy of the data collection form is 
attached as Annex 4. 
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Reliability 
Rigour was ensured in this study by following the established sampling frame with minimal 
amendments to it.  The process of objective measure through direct observation as opposed to 
subjective measure, recall, or self-reported availability serves to increase the validity of the study.  
Finally, the tool was been piloted in ongoing collaborative monitoring of medicine price and 
availability studies.  
 
Data Analysis 
The availability of each medicine was recorded in the public and mission facilities visited. 
Availability was thus noted as the percentage of facilities where a medicine was found on the day of 
the survey data collection.  Availability of brands and generics was not distinguished, in order to 
establish the complete (overall) availability of each medicine.  It is notable that brand name 
medicines are rarely found in mission or public facilities (WHO / HAI, 2010).   
 
Quantitative analyses of the specific sub-sets of data for key chronic NCD medicines and CD 
medicines were carried out.  Comparisons were made between CD and NCD medicines, between 
rural and urban areas, and between mission and public facilities.  Availability of CD and NCD 
medicines was calculated as the total number of medicines available as a percentage of all 
observations done in each category for rural vs. urban and mission vs. public.  The Chi-squared test 
was then used to compare the categories for differences.  Finally, to understand if the availability of 
NCD medicines differed by indication, the availability of each individual medicine was analyzed and 
compared relative to location and facility type. 
 
Ethical Statement  
The Ministry of Health and other key partners were informed of the study and an MOH endorsement 
letter was obtained from the Deputy Chief Pharmacist (Annex 3); assuring facilities (a) of their (and 
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their data’s) anonymity and (b) that data collectors are not acting in any way as regulators.  This 
letter helped to facilitate data collection at facility level.  Collaborative data collection on medicine 
prices and availability has been regularly done in Kenya across sectors and health facility levels and 
no public sector facilities resisted giving information to the data collectors.  
 
The names of facilities participating in the study are not reported, and data has been pooled across 
facilities, minimising any risk of being singled out as a poor performer. No data on individual 
patients was collected, and no patients were spoken to or involved in any way. 
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RESULTS 
 
Response rates and description of study facilities 
A total of 56 facilities were included in the survey.  Two provinces had eight instead of ten facilities 
surveyed, due to logistical constraints faced by the data collectors, giving a facility response rate of 
93%.  The sample included 49 public sector facilities and seven mission sector facilities.  Thirty 
facilities were surveyed in rural settings, and 26 in urban settings.  This is illustrated in Table 1 
below. 
 
Table 1: Description of the Facilities Surveyed 
Facility Type 
Mission Public Total 
  
Urban or Rural N % N % N 
Rural 4 57.1 26 53.1 30 
Urban 3 42.9 23 46.9 26 
Total 7 100 49 100 56 
 
 
Availability of medicines 
The availability of medicines is detailed in Tables 2 below for communicable diseases (CD).  
Availability is presented as the percentage of the facilities surveyed which had the medicine 
available.  Nearly all the CD medicines (13 out of 16) were available in more than half the health 
facilities surveyed. The most commonly available CD medicines were oral rehydration solution for 
diarrhoea and the antibiotic, cotrimoxazole, both available in more than 90% of facilities. The least 
available CD medicines were those used primarily for the treatment of sexually transmitted 
infections (ciprofloxacin, ceftriaxone and metronidazole) which were available in less than half the 
facilities.  More than 70% of facilities had anti-retroviral medicines and first-line antimalarial 
medicines (artemether / lumefantrine) in stock.  
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Table 2: Availability of medicines for Communicable Diseases 
 
Frequency of 
observation 
(N=896 
observations) 
 % facilities with 
medicine available 
(N=56 ) 
ORS sachet for 500mL 55 98.2 
Cotrimoxazole tab 80/400mg 51 91.1 
Albendazole tablet 400mg 48 85.7 
Amoxicillin cap / tab 250mg 46 82.1 
Amoxicillin susp 125mg/5mL 46 82.1 
Cotrimoxazole suspension 8/40 mg/mL 46 82.1 
Zinc sulfate dispersible tab 20mg 46 82.1 
AZT tablet 300mg 41 73.2 
Nevirapine tablet 200mg 41 73.2 
AZT / 3TC  combination tab 300 / 150mg 40 71.4 
Artemether / lumefantrine tab 20/120mg 40 71.4 
Quinine dihydrochloride inj 300mg/mL (2mL amp) 35 62.5 
Gentamicin injection 10mg/mL or 40mg/mL (2mL amp) 30 53.6 
Ciprofloxacin tab 250mg or 500mg 26 46.4 
Ceftriaxone powder for inj 250mg or 1g 23 41.1 
Metronidazole tablet 200mg or 400mg 18 32.1 
Total observations 632  
 
 
 
Table 3 lists the medicines available for non-communicable diseases (NCD).  The most available 
NCD medicine was the anti-inflammatory, ibuprofen.  The second most available, aspirin (ASA), is a 
standard treatment for the majority of people with heart disease or stroke (WHO, 2003).  It is an 
inexpensive and commonly manufactured essential medicine, yet it was only available in 75% of the 
facilities surveyed.  Insulin is a vital life-saving medicine for people with type I diabetes, but its 
availability was only 43% in the facilities surveyed.  Hydrochlorothiazide is also a widely 
recommended and inexpensive first line treatment for hypertension in older people; it was only found 
in half of the facilities surveyed.  Bar one facility, essential medicines for the treatment of gout 
(allopurinol) and glaucoma (acetazolamide) were not available at all. 
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Table 3: Availability of Medicines for Non-Communicable Diseases 
 Frequency of 
observations 
(N=672 
observations) 
% facilities with 
medicine available 
(N=56) 
Ibuprofen tab / cap 200mg 45 80.4 
ASA (aspirin) tablet 300mg 42 75.0 
Furosemide tab 40mg 36 64.3 
Metformin tab 500mg 31 55.4 
Atenolol tab 50mg 30 53.6 
Hydrochlorothiazide tablet 25mg 28 50.0 
Benzhexol HCl tablet 5mg 26 46.4 
Glibenclamide tab 5mg 26 46.4 
Insulin human 30/70 injection (10mL) 24 42.9 
Enalapril tablet 5mg 17 30.4 
Allopurinol tablet 100mg 1 1.8 
Acetazolamide tablet 250mg 0 0 
Total observations 306  
 
 
 
NCD grouped by clinical indication are presented in Table 4.  Medicines for heart disease were the 
most available (23.5%), while medicines for Parkinson’s disease, gout and glaucoma were the least 
available (7.4%, 0.3% and 0% respectively). 
 
Table 4: Relative availability of NCD medicines 
Disease type Total observations (N) 
Relative 
Availability (%) 
Heart Disease 83 23.5 
Diabetes 81 22.9 
High Blood Pressure 75 21.2 
Arthritis 45 12.7 
Stroke 42 11.9 
Parkinson’s Disease 26 7.4 
Gout 1 0.3 
Glaucoma 0 0.0 
Total 353 100.0 
 
 
 
Comparisons of availability of CD and NCD medicines 
Of the 896 possible individual observations of CD medicines, 632 (70.5%) were recorded as 
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available on the day of visit, compared to 306 (45.5%) of 672 possible individual observations of 
NCD medicines (Table 5). These difference in availability are statistically significant (chi-
squared=98.8, p<0.001). 
 
Table 5: Comparison of overall availability of CD and NCD medicines 
 Medicines available 
(%) 
Medicines not available 
(%) Total (%) 
CD 632 (70.5%) 264 (29.5%) 896 (100%) 
NCD 306 (45.5%) 366 (54.5%) 672 (100%) 
All medicines 938 (59.8%) 630 (40.2%) 1568 (100%) 
p-value (chi-squared 
test) chi-sq=98.8, p=<0.001  
 
 
 
Table 6 below reveals statistically significant differences in availability of NCDs medicines between 
rural and urban facilities (p=0.007), but not for CD medicines (p=0.190).   
 
Table 6: Availability of CD and NCD medicines in rural vs urban facilities 
CD NCD  
All observations Availability All observations Availability 
Rural 480 348 (72.5%) 360 146 (40.6%) 
Urban 416 284 (68.3%) 312 160 (51.3%) 
Total 896 632 (70.5%) 672 306 (45.5%) 
p-value (chi-
squared test) chi-sq=1.721, p=0.190 chi-sq=7.328, p=0.007 
 
 
Table 7 below reveals no statistically significant difference in CDs vs. NCDs medicines when 
comparing availability in mission and public facilities. 
 
Table 7: Availability of CD and NCD medicines in mission and public facilities 
CD NCD  
All observations Availability (%) All observations Availability 
Mission 112 75 (66.9%) 84 39 (46.4%) 
Public 784 557 (71.0%) 588 267 (45.4%) 
Total 896 632 (70.5%) 672 306 (45.5%) 
p-value (chi-
squared test) chi-sq=0.602, p=0.438 chi-sq=0.003, p=0.953 
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Availability of NCD medicines in urban and rural facilities 
To understand how the availability of NCD medicines varied by individual medicine within different 
settings, the availability was calculated as the percentage of total observations done on each 
medicine, and was compared between urban vs. rural (Table 8).  Only hydrochlorothiazide and 
insulin 30/70 showed a significant difference in availability by urban and rural comparison. 
 
Table 8: Availability of medicines for NCD by urban vs. rural 
Rural 
(N=30) 
Urban 
(N=26)   
 
N % N % chi-sq p-value 
ASA (aspirin) tablet 300mg 21 70.0 21 80.8 0.846 0.358 
Allopurinol tablet 100mg 0 0.0 1 3.8 1.154 0.284 
Atenolol tab 50mg 14 46.7 16 61.5 1.216 0.271 
Benzhexol HCl tablet 5mg 12 40.0 14 53.8 1.054 0.306 
Enalapril tablet 5mg 9 30.0 8 30.8 0.004 0.951 
Furosemide tab 40mg 18 60.0 18 69.2 0.508 0.476 
Glibenclamide tab 5mg 14 46.7 12 46.2 0.001 0.969 
Hydrochlorothiazide tablet 25mg * 11 36.7 17 65.4 4.513 0.034 
Ibuprofen tab / cap 200mg 23 76.7 22 84.6 0.548 0.459 
Insulin human 30/70 injection (10mL) * 9 30.0 15 57.7 4.284 0.038 
Metformin tab 500mg 15 50.0 16 61.5 0.737 0.391 
* statistically significantly different between rural and urban 
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DISCUSSION  
 
Medicines for CDs are generally more available than are medicines for NCDs, at 70.5% and 45.5% 
respectively.  The overall availability of NCD medicines is relatively poor in Kenya’s public health 
sector, especially for gout, glaucoma, diabetes and standard treatments for hypertension, all of which 
were available in less than half the facilities visited.  NCD medicines are less available in rural 
settings (40.6%) than they are in urban settings (51.3%), while medicines for CDs do not reveal a 
rural vs. urban availability difference.   
   
These results are in line with those of previous studies on availability of medicines in Kenya and 
other African countries.  The most recent data from Kenya on overall availability of a mixed basket 
of 36 essential medicines (for both CD and NCD combined) was 67% (MOH, WHO, HAI Africa, 
2010).  Indeed, an analysis of 30 medicines in 40 low- and middle-income countries revealed that 
medicines for chronic diseases are found less frequently (36%) in the public sector than medicines 
for acute diseases (53.5%) (Cameron et al. 2009). 
 
Other studies have found lower availability of a basket of essential medicines in rural areas (MOH, 
WHO, HAI Africa, 2010; WHO / HAI, 2010) which was confirmed in these results for NCD 
medicines specifically.  As an apparent response to such ongoing findings in rural areas, Primary 
Health Care and rural health facilities will have an increased focus in the coming years (Kenya 
Health Sector Strategic Plan, 2012). 
 
In past studies (MOH, WHO, HAI Africa, 2010; WHO / HAI, 2010) availability was usually 
comparable in the public and mission facilities.  This was similarly found in these results, where 
there was no significant difference in the availability of NCD and CD medicines between these two 
sectors.   
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The burden of NCDs is rising in Africa (WHO, 2008) and the body of evidence on poor availability 
of medicines for NCDs is becoming established and growing (WHO / HAI, 2010, Cameron et al. 
2009), yet inadequate attention is being focused on these areas.  For many years, priorities and 
urgencies for funding, training, planning and governmental health strategy have been focused on 
medicines and vertical programs for CD such as HIV, tuberculosis and malaria.  The same urgency 
and comprehensive approach needs to be applied to NCDs and their treatment.   
 
Low availability of medicines in the public sector potentially forces patients to seek medicines in the 
private sector, which historically has better availability but higher prices and less affordability (WHO 
/ HAI, 2010).  Older persons may already exhibit under-use of health services, and the relative lack 
of essential medicines for the diseases they most commonly suffer contributes to the under-use.  This 
mini-thesis highlights the need for increased attention towards the management of chronic diseases; 
financing, selection, procurement and supply of essential medicines; access to medicines for older 
people; and equity in health systems. 
 
The study has certain limitations.  Although based on a validated methodology, the study entails a 
relatively small sample size of 56 facilities.  It is also a snapshot, cross-sectional assessment (subject 
to delivery schedules) as opposed to a more dynamic average availability over time assessment.   
 
Kenya’s health facilities in the public and mission sectors are categorized into six levels according to 
their infrastructure, budget, human resources, and the types of services (including essential 
medicines) they offer.  It was beyond the scope of this study to further analyze the availability of 
medicines by facility level but this is a valid idea for a deeper study. 
 
Not all essential medicines for each NCD were studied.  For example, only one type of insulin was 
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surveyed, and no eye-drops for glaucoma were included in the study.  Availability findings could 
also be affected by different strengths or dosage forms from those included in the study.   
 
It is also noted that while HIV is “crossing the line” between being a CD and a chronic disease, for 
the purposes of this study, medicines to manage HIV were considered as medicines for CD, and 
indeed HIV prevalence is highest in younger people in Kenya.  Finally, there are other reasons 
besides age-related inequities for the lower prioritization of NCDs vs CDs and this study is limited in 
its design to comprehensively determine, differentiate and describe the range and depth of these 
reasons.   
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CONCLUSIONS AND RECOMMENDATIONS 
 
This study reveals low availability of NCD medicines as compared to medicines for CD.  A number 
of varied factors may lead to the lower availability or prioritisation of essential medicines for NCDs.  
Inequity -- as a potential age-related factor -- may only be one of them, and this study may be 
considered an initial step to a deeper analysis on the factors affecting health and medicines access 
among elderly Kenyans.  Studies on other factors, including health worker education and awareness 
on NCDs and older people, health- and medicines- policy making processes, budgetary allocation for 
medicines, and treatment guidelines for NCDs could also be carried out to deepen the evidence base 
on access to medicines for older people in Kenya.  A study on the role of local pharmaceutical 
companies in Kenya in improving availability of NCD medicines could also be considered (UNIDO, 
2010). 
 
People with NCDs need a reliable supply of medicines to manage their chronic conditions, and there 
is an urgent need to improve the availability of NCD medicines in Kenya’s public sector.  Attention 
to the procurement, management, supply and financing of medicines for NCDs should be improved:  
Standard treatment guidelines for NCDs and the National Essential Medicines Lists should be 
developed, reviewed and revised based on the most current evidence.  Health workers training should 
ensure awareness of guidelines and evidence.  National Social Health Insurance should cover 
medicines for chronic disease. 
 
Access to essential medicines is a human right, and forms the foundation of Kenya’s public primary 
health care system.  However, and more than thirty years after the introduction of the essential 
medicines concept, there remains gravely inadequate amounts of medicines available to those in 
need.  All of the barriers leading to low availability (economic constraints, competing priorities, 
bureaucratic obstacles, lack of political will) can be overcome to help people in their struggle to 
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realize their right to health.  The elderly are a particularly vulnerable group in this struggle, and 
special attention to their needs should be an urgent priority for the government and its partners 
supporting the health sector. 
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ANNEXES 
 
Annex 1. INFORMATION SHEET FOR FACILITY MANAGERS 
 
   UNIVERSITY OF THE WESTERN CAPE 
   School of Public Health 
 
   Private Bag X17 ●BELLVILLE● 7535 ● South Africa 
   Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
 
 
Dear facility manager 
 
I am Christa Cepuch, a student at the SOPH, University of the Western Cape. As part of my Masters in Public 
Health, I am required to do a research project on a public health issue of relevance. I will be focusing on 
availability of medicines for communicable versus non-communicable diseases, and how this may be an 
indicator of poor access to medicines by elderly people. I am accountable to Prof Helen Schneider who is 
contactable c/o SOPH Fax: 021 959 2872 or by e-mail at hschneider@uwc.ac.za. 
 
The research seeks to achieve three objectives: 
 
In the public sector in Kenya: 
1. To assess the availability of medicines for the following communicable diseases (CD): diarrhea, HIV, 
malaria, pneumonia 
2. To assess the availability of medicines for the following non-communicable diseases (NCD) common 
in older populations: arthritis, diabetes, gout, glaucoma, heart disease, hypertension, stroke 
3. To compare the availability of medicines for CD and NCD and draw conclusions on possible age-
related inequities in access 
 
Data collection will involve an assessment through observation of the availability of the targeted medicines on 
the day of the visit, and questions on the prices charged for each medicine. These observations will be done by 
trained data collectors who will record this information on specially designed forms.  These observations are 
very similar to the routine assessments of medicines availability in Kenyan facilities that you may have 
participated in already.  
 
Your facility was chosen through a random sampling procedure. The data from your facility will be combined 
with that of other facilities and your facility’s name will not appear in the report and will not be singled out in 
any way.  
 
There will also be no direct benefits to the facility if you do participate. 
 
Given that the purpose of data collection is research rather than routine operations, you are requested to sign 
an informed consent form.  You are free to withdraw at any stage and this will have no adverse consequences 
for you or your work.  Your identity, as well as that of the information you provide, will remain anonymous.   
 
Please feel free to contact myself, Christa Cepuch at email ccepuch@gmail.com or tel 0733 615 189 or my 
supervisor, Prof Helen Schneider, of the University of the Western Cape, South Africa via email 
hschneider@uwc.ac.za. 
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Annex 2. WRITTEN CONSENT FORM 
 
Date:                     
Interviewer:  
UWC Student no: 
Tel: _____________ Fax: ________________________ 
E-mail: 
Institution: 
Interviewee’s pseudonym:  
Place at which the interview was conducted:   ______________________________________ 
 
Thank you for agreeing to allow me to visit your facility. What follows is an explanation of the purpose and 
process of this visit to which you are requested to sign consent.  
 
I am Christa Cepuch, a student at the SOPH, University of the Western Cape. As part of my Masters in Public 
Health, I am required to do a research project on a public health issue of relevance. I will be focusing on 
availability of medicines for communicable vs non-communicable diseases and how this may be an indicator of 
poor access to medicines by elderly people. I am accountable to Prof Helen Schneider who is contactable c/o 
SOPH Fax: 021 959 2872 or by e-mail at hschneider@uwc.ac.za. 
 
Data collection involves an assessment through observation of the availability of medicines in your facility on 
the day of the visit, and questions on the prices charged for each medicine. I will only ask you about the 
availability of a list of medicines in your facility, and their prices. 
 
At all times, I will keep the source of the information confidential and refer to you and your facility by an 
anonymous facility code. I shall keep any other records of your participation locked away at all times, and 
destroy them after the data has been collected. 
 
If there is anything that you would prefer not to discuss, you are free to say so.  
 
I shall keep the contents of the above research confidential in the sense that the pseudonym noted above will be 
used in all documents which refer to the interview. The contents will be used for the purposes referred to above, 
but may be used for published or unpublished research at a later stage without further consent. Any change from 
this agreement will be renegotiated with you. 
 
Signed by interviewer: 
 
Signed by participant:                                 
Date: 
Place: 
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Annex 3. ENDORSEMENT LETTER FROM THE MOH 
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Annex 4. DATA COLLECTION FORM 
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